Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer

Author:

Furukawa Masaru1,Ishii Yasutaka1ORCID,Serikawa Masahiro1ORCID,Tsuboi Tomofumi1,Tatsukawa Yumiko1,Hirano Tetsuro1,Nakamura Shinya1,Ikemoto Juri1ORCID,Kiyoshita Yusuke1,Saeki Sho1,Tamura Yosuke1,Miyamoto Sayaka1,Nakamura Kazuki1,Yamashita Yumiko1,Iijima Noriaki1,Uemura Kenichiro2,Oka Shiro1

Affiliation:

1. Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan

2. Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan

Abstract

Objectives: We aimed to compare the utility of covered self-expanding metal stents (CSEMSs) with that of plastic stents (PSs) for biliary drainage during neoadjuvant chemotherapy in patients with borderline resectable pancreatic cancer. Methods: Forty patients with borderline resectable pancreatic cancer underwent biliary stenting during neoadjuvant chemotherapy at Hiroshima University Hospital. PSs and CSEMSs were placed in 19 and 21 patients, respectively. Two gemcitabine-based regimens for chemotherapy were used. Treatment outcomes and postoperative complications were compared between both groups. Results: The incidence of recurrent biliary obstruction was significantly lower in the CSEMS group (0% vs. 47.4%, p < 0.001), and the median time to recurrent biliary obstruction in the PS group was 47 days. There was no difference in the incidence of other complications such as non-occlusive cholangitis, pancreatitis, and cholecystitis between the two groups. Delays in the chemotherapy schedule due to stent-related complications were significantly frequent in the PS group (52.6% vs. 4.8%, p = 0.001). There was no significant difference in the incidence of postoperative complications between the two groups. Conclusions: CSEMSs may be the best choice for safely performing neoadjuvant chemotherapy for several months in patients with borderline resectable pancreatic cancer with bile duct stricture.

Publisher

MDPI AG

Subject

General Medicine

Reference33 articles.

1. The Editorial Board of the Cancer Statistics in Japan (2022, November 12). Cancer Registry and Statistics. Cancer Information Service NCCJ. Cancer Statics in Japan 2019. Foundation for Promotion of Cancer Research (FPCR). Available online: https://ganjoho.jp/en/professional/statistics/brochure/2019_en.html.

2. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020

3. National Comprehensive Cancer Network (2022, November 15). NCCN Clinical Practice Guidelines in Oncology—Pancreatic Adenocarcinoma. Version 1. Available online: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.

4. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: A multi-institutional survey by the Japanese Society of Pancreatic Surgery;Kato;J. Hepatobiliary Pancreat. Sci.,2013

5. Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: A synopsis;Okusaka;Pancreas,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3